Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use PEMFEXY safely and effectively. See full prescribing information for PEMFEXY. PEMFEXY™ (pemetrexed injection), for intravenous use Initial U.S. Approval: 2004
Medication labelWhy this: Advisory · dailymed-prescription
PEMFEXY™ is indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. as a single agent for the treatment of patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy. Limitations of Use: PEMFEXY is not indicated for the treatment of patients with squamous cell NSCLC [see Clinical Studies 14.1]. PEMFEXY is indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.
- generic_name
- pemetrexed
- product_names
- pemetrexed
- ndc
- 71390-250, 71390-250-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en